Neuroinflammation in Alzheimer's Disease represents a critical pathological mechanism that mediates the relationship between amyloid-beta deposition, tau pathology, and downstream neurodegeneration. Chronic neuroinflammation is now recognized not merely as a secondary response to amyloid and tau pathology but as an active driver of disease progression that amplifies synaptic loss, neuronal death, and cognitive decline 1.
The neuroinflammatory response in Alzheimer's disease involves complex interactions between resident brain immune cells (microglia and astrocytes), peripheral immune cells, neurons, and the vascular system. This pathway page explores:
Microglia are the primary immune cells of the central nervous system, originating from yolk sac progenitors during embryogenesis 2. In the healthy brain, microglia maintain homeostasis through:
In Alzheimer's disease, microglia undergo phenotypic changes in response to amyloid-beta plaques, tau pathology, and neuronal damage. This activation follows a continuum from beneficial to harmful:
Even before significant amyloid deposition, genetic risk factors for AD influence microglial behavior. The TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) variant R47H significantly increases AD risk 3. TREM2 is expressed on microglia and recognizes amyloid-beta as a ligand, triggering intracellular signaling through the adaptor protein DAP12.
As amyloid plaques form, microglia cluster around plaques in a characteristic pattern. These disease-associated microglia (DAM) or microglial neurodegenerative phenotype (MGnD) upregulate:
Prolonged activation leads to a shift from protective to damaging inflammation:
Astrocytes undergo dramatic changes in AD, adopting reactive phenotypes. Research has identified two main reactive astrocyte states 4:
A1 reactive astrocytes: Pro-inflammatory, neurotoxic
A2 reactive astrocytes: Neuroprotective
Reactive astrocytes in AD:
| Cytokine | Source | Role in AD | Therapeutic Target |
|---|---|---|---|
| IL-1β | Microglia, Astrocytes | Promotes tau phosphorylation, synaptic loss | IL-1 receptor antagonists |
| TNF-α | Microglia, Astrocytes, Neurons | Drives neurotoxicity, disrupts BBB | Anti-TNF biologics |
| IL-6 | Microglia, Astrocytes, Neurons | Modulates Aβ processing | IL-6 receptor antibodies |
| IL-18 | Microglia | Induces IFN-γ production | IL-18 binding protein |
The complement system plays a dual role in AD 5:
Neuroinflammation actively accelerates tau pathology through multiple mechanisms:
This creates a self-propagating cycle where amyloid triggers inflammation, which accelerates tau pathology, which increases neuronal damage, which further amplifies inflammation.
Genome-wide association studies (GWAS) have identified numerous immune-related AD risk genes 6:
The NLRP3 inflammasome is a key driver of neuroinflammation in AD 7:
Multiple anti-inflammatory approaches have been tested:
| Approach | Drug/Strategy | Status | Challenges |
|---|---|---|---|
| NSAIDs | Ibuprofen, Naproxen | Failed | Timing, dose, CNS penetration |
| Minocycline | Antibiotic with anti-inflammatory effects | Mixed results | Limited CNS efficacy |
| Canakinumab | Anti-IL-1β antibody | Ongoing | Peripheral vs CNS targeting |
| AL002 | Anti-TREM2 antibody | Phase 2 | Mechanism-dependent effects |
Neuroinflammation in Alzheimer's disease represents a central pathological mechanism that bridges amyloid-beta deposition, tau pathology, and clinical progression. While anti-inflammatory treatments have so far failed in clinical trials, emerging understanding of specific inflammatory pathways and microglial biology offers new therapeutic targets. The key challenges include:
Future successful approaches will likely combine anti-amyloid, anti-tau, and immunomodulatory strategies for comprehensive disease modification.
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 7 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |
Overall Confidence: 32%